Products for Research Use Only

SB 220025

CAT: 0804-HY-112291-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112291-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM) . SB 220025 also inhibits p56Lck and PKC with IC50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation[1][2].
CAS Number
165806-53-1
UNSPSC
12352005
Hazard Statement
H301, H315, H319, H335
Target
P38 MAPK; PKC; Src
Type
Reference compound
Related Pathways
Epigenetics; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sb-220025.html
Purity
99.90
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCNCC4)=N1
Molecular Formula
C18H19FN6
Molecular Weight
338.38
Precautions
H301, H315, H319, H335
References & Citations
[1]Tomizawa A, et al. Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci. 2009 Sep 9;85 (11-12) :457-61.|[2]Jackson JR, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther. 1998 Feb;284 (2) :687-92.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Lck; p38 MAPK; PKC